CA3 (CIL56) Clinical Trials

Size	Price	Qty
5mg	USD 147
25mg	USD 447

Clinical Trials

A Phase 2 clinical trial is currently recruiting participants to evaluate this intervention across neurodegenerative and cognitive conditions, specifically memory impairment, mild cognitive impairment, and Parkinson's disease. Sponsored by major academic and clinical institutions—including The University of Queensland, Johns Hopkins University, and the Cleveland Clinic Lou Ruvo Center for Brain Health—the study employs a double-blind, randomized, controlled crossover design. This evaluation seeks to establish whether target pathway modulation can mitigate cognitive decline and functional memory deficits in affected patient populations.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04643327	Recruiting	Parkinson Disease\|Mild Cognitive Impairment\|Memory Impairment	The University of Queensland\|Queensland University of Technology\|Johns Hopkins University\|Cleveland Clinic Lou Ruvo Center for Brain Health\|Royal Brisbane and Women''s Hospital	2021-02-09	Phase 2

(data from https://clinicaltrials.gov, updated on 2024-05-22)

Check the CA3 (CIL56) product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

CA3 (CIL56) potently inhibits YAP1/TEAD transcriptional activity, suppressing downstream gene expression and promoting iron-dependent reactive oxygen species accumulation that induces ferroptosis. By disrupting targeted transcriptional networks and inducing oxidative cell death, this mechanism provides a theoretical basis for therapeutic evaluation in clinical conditions including Parkinson's disease and associated cognitive impairments.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).